Abstract: A method for the prevention and/or treatment of dementia in a human subject; the method comprising the step of administering an effective amount of a composition comprising at least one carotenoid selected from the group consisting of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid.

Abstract: Disclosed is a method of improving the cognitive function of a cognitively healthy human adult, the method comprising administering to the human adult an effective amount of a composition comprising lutein, zeaxanthin and meso-zeaxanthin and at least one omega-3 fatty acid, over a period of at least 24 months, the improved cognitive function being a detectable improvement in: spatial working memory as measured by the CANTAB Connect Research software SWM task; and/or reduced reaction time as measured by the CANTAB Connect Research Software RTI task.

Abstract: A method for the prevention and/or treatment of mild cognitive impanment in a human subject; the method comprising the step of administering an effective amount of a composition comprising each of the following: lutein, zeaxanthin, meso-zeaxanthin, vitamin E, and at least one omega-3 fatty acid.

Abstract: A method for the prevention and/or treatment of dementia in a human subject; the method comprising the step of administering an effective amount of a composition comprising at least one carotenoid selected from the group consisting of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid.

Abstract: Disclosed is a plant-derived flavonol-containing dry composition suitable for human consumption, wherein at least 25% of the plant-derived material in the composition comprises polyphenols, together with uses thereof.

Abstract: Meso-zeaxanthin compositions for pharmaceutical use and use of meso-zeaxanthin to increase the deposition of macular pigment in the human eye, and for the therapeutic treatment or prophylaxis of diseases and disorders of the macula, in particular age-related macular degeneration (AMD).

Abstract: Meso-zeaxanthin compositions for pharmaceutical use and use of meso-zeaxanthin to increase the deposition of macular pigment in the human eye, and for the therapeutic treatment or prophylaxis of diseases and disorders of the macula, in particular age-related macular degeneration (AMD).

Abstract: Disclosed is a method of producing a polyphenol-containing composition derived from grapes, the method including: preparing a liquid grape extract which includes polyphenols; contacting the liquid extract with a separation medium which fractionates the components of the extract; and recovering that fraction in which the polyphenols are present. Also disclosed is a method of enriching the composition with added flavonol.

Abstract: Disclosed are compositions which include creatine and Aloe Vera extract, for the purpose of increasing the creatine supply deposits of human beings, and to improve their intestinal health. The composition is presented as a drink, either constituted from a dry powder or in liquid form. Also disclosed is a method of increasing the stability of a drink or semi-liquid solid comprising creatine and Aloe Vera extract by storing the compositions below ambient temperature, preferably 0-8° C.

Abstract: A flavonol-containing dry composition derived from wine and useful as a food supplement is provided wherein at least 25% of the composition derived from wine includes polyphenols and at least 1.0% w/w of the composition is flavonol.

Abstract: Disclosed is a flavonol-containing dry composition suitable for human consumption, together with uses thereof.

Abstract: Disclosed is an acidic composition for human consumption, comprising creatine. In particular the composition is conveniently an isotonic drink for storage at 4.degree. C., or is a dry stable powder which may be stored at ambient temperature.

Abstract: It has been discovered that the unfavorable effects observed in weight reduction treatments based on severe dietary restriction (less than 600 Kcals/day) or total fasting (as regards fat, carbohydrates and aminoacids) are avoided by the administration of aminoacids and carbohydrates in critical but much lower amounts than has been believed to be necessary. Nitrogen loss with aminoacid intake between about 15 and 30 g per day is affected by carbohydrate intake. Nitrogen balance is maintained and ketosis and water retention are controlled when the daily intake includes, in addition to necessary minerals and vitamins, at least 15 g of aminoacids in the proportions required by man, and from 15 to 75 g, preferably 30 to 45 g, of carbohydrates, with a total caloric value of from 160 to about 600 Kcals, preferably less than 400 Kcals, very desirably less than 360 Kcals, and optimally in the range of from 180 to 360 Kcals.